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Aims. To study the inﬂuence of P-glycoprotein (P-glycoprotein, ABCB1, MDR1) function on placental transfer of lopinavir with
ritonaviratdiﬀerentalbuminconcentrations.Methods.Cotyledonswereperfusedwithlopinavir,ritonavir,andtheinternalcontrol
antipyrin, at various albumin concentrations (10, 30, 40g/L). After the control phase of each experiment, the P-glycoprotein
inhibitor ciclosporin A was added at middle perfusion (45 minutes). Fetal Transfer Rate (FTR) and Clearance Index (CLI) were
compared between the 2 phases. Results. In the control phase, the clearance index of lopinavir decreased from 0.401 ± 0.058 to
0.007 ± 0.027, as albumin concentrations increased from 10g/L to higher concentrations (30, 40g/L). When adding ciclosporin
A at physiological albumin concentrations, the clearance index of lopinavir increased signiﬁcantly 10.3 fold (95% of CI diﬀerence
[−0.156, −0.002], P = .046) and became positive for ritonavir. Conclusions. Even at high albumin concentrations, inhibition
of placental P-glycoprotein increased placental transfer of lopinavir, suggesting that this eﬄux pump actively reduces placental
transfer of the drug. This mechanism may play a role in fetal exposure to maternal antiretroviral therapy.
Copyright © 2009 Pierre-Francois Ceccaldi et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
What is Already Known about this Subject? We founded
previously that albumin concentration had a strong impact
on placental transfer of lopinavir and ritonavir. When
the concentration of albumin was increased to 40g/L, we
observed a marked decrease of placental transfer for both
ritonavir and lopinavir.
Our ﬁndings suggest that P-glycoprotein in placentas
fromHIV-infectedwomenwouldcontributetomodulatethe
maternofetal transport of antiretrovirals across the placental
barrier and consequently diminish fetal exposure to these
compounds.
What this Study Adds? This study uses the well-known
human cotyledon-perfused model to investigate the P-
glycoprotein eﬀect on the placental transfer of lopinavir and
ritonavir at low (10g/L) and physiologic (30 and 40g/L)
albuminconcentrations.Eachplacentaisitsowncontroland
ciclosporinAwascoperfusedatmiddletimeoftheperfusion.
Expression on placenta of P-glycoprotein was analyzed.
The clearance index of lopinavir and ritonavir increased
following the addition of ciclosporin, even at physio-
logic albumin concentration. Expression on placenta of
P-glycoprotein was wide, and there was no signiﬁcative
correlation with clearance index of lopinavir.
Lopinavir coformulated with low-dose ritonavir (Kaletra
, Abbott) is commonly used in ﬁrst-line combination
antiretroviral therapies for HIV-infected patients. It is
also recommended for the prevention of mother-to-child
transmission because of its capacity to reduce HIV-1 RNA
concentrations to below the detection limit in a few weeks2 Obstetrics and Gynecology International
[1]. However, in view of fetal toxicity observed in animal
studies, lopinavir/ritonavir is classiﬁed under category C by
the US Food and Drug Administration (FDA). The degree of
concern about its safety to the fetus depends on the amount
of placental transfer of the drug. Using the ex vivo perfused
human placental cotyledon, we reported for lopinavir a
placental transfer rate of 3.3% ± 0.5 in the presence of
physiological albumin concentrations [2]. In a clinical study
of paired cord and maternal blood at delivery, the ratio was
0.2 ± 0.13 [3]. These concordant experimental and clinical
data suggest that the fetus is usually exposed to relatively low
concentrations of lopinavir during maternal therapy.
The placental transfer of drugs with molecular weights
800Da such as lopinavir and most antiretovirals is known
to be inﬂuenced by various physicochemical properties and
by the amount of protein binding. There is now a large
body of evidence suggesting that eﬄux proteins play an
important role in reducing the amount of placental transfer
of some drugs. P-glycoprotein (P-glycoprotein, ABCB1) is
an active ATP-dependent drug-eﬄux pump highly expressed
in the maternal facing cell membrane of trophoblasts [4].
This protein seems to play an important role in limiting the
maternal-fetal transfer of protease inhibitors (PIs). Recently
a study has shown a 3.3-fold increased expression of P-
glycoprotein in placentas of HIV-infected women. It could
be theoretically associated with a decreased transfer of
substrates of P-glycoprotein, such as PI [5]. Another study
reported a higher expression of P-glycoprotein in early of
pregnancy than at term, which may have an impact on pla-
cental transfer of PI-like lopinavir, which is a P-glycoprotein
substrate[6].Astudyonculturedplacentalchoriocarcinoma
cells highlighted that P-glycoprotein inhibitor ciclosporin
A could increase the cellular uptake of the P-glycoprotein
substrates [7]. Placental P-glycoprotein seems to play a
protective role for the fetus against drugs and xenobiotics
[8].
The goal of this work was to study the inﬂuence of the
activity of P-glycoprotein and the concentration of perfused
albumin on the transplacental passage of lopinavir and
ritonavir on the experimental model of the perfused human
cotyledon.
2. Methods
2.1. Materials. Placentas were perfused in an open double
circuit according to a method modiﬁed from that of Schnei-
der and Huch as previously described [9, 10]. Placentas were
collected after uneventful term (37–42 weeks gestational age)
vaginal deliveries from HIV-seronegative women receiving
no drug treatment, except oxytocin or epidural anesthesia
during labor. Each patient gave written informed consent
to participate in the study. The maternal and fetal solutions
were prepared with Earle medium with 10, 30, or 40g/L
bovine serum albumin (Euromedex, France). Lopinavir and
ritonavir were used in a powder base provided by Abbott
Laboratories (Rungis, France). The targeted concentrations
infused in the maternal compartment were 6mg/L for
lopinavir and 3mg/L for ritonavir. Ciclosporin A (10μM) is
a well-studied molecule which has an inhibitory eﬀect on P-
glycoproteinandmaybeusedwithcautionduringpregnancy
[11].
2.2. Placental Perfusion Technique. Perfusion experiments
were started within 20 minutes after delivery. After a visual
examination for lack of evident lesions on the chorionic
plate, a truncal branch of the chorionic artery supplying a
selected cotyledon and the associated vein was cannulated.
The fetal circulation was established at a ﬂow rate of
6mL/min in order to ensure a balance between arterial
and fetal venous ﬂows. Placentas with evidence of vascular
leakage were discarded. On the maternal side the perfused
area progressively whitened, which allowed visualization
of the chosen cotyledon. The cotyledon was placed in
the perfusion chamber with the maternal surface upward.
The perfusion chamber was maintained at 37◦C through a
circulating thermostat bath. The intervillous space on the
maternal side was perfused by two needles piercing the
basal plate. The maternal ﬂow rate was 12mL/min. The
pH was adjusted to 7.4 ± 0.1 for the maternal and 7.3 ±
0.1 for the fetal solutions, respectively, by the addition of
a solution of sodium bicarbonate and hydrochloric acid.
The perfusion length was 95 minutes. Combination of
lopinavir, ritonavir, and a freely diﬀusing marker antipyrin
(20mg/L) (Sigma, France), were perfused into the maternal
reservoir. Ciclosporin A was added at middle time of the
perfusion, that is, 45 minutes. Samples from the maternal
and fetal solutions were collected in order to determine
concentrations of antipyrin, lopinavir, and ritonavir at 25,
30, 35, 40 minutes for the control phase and 75, 80, 85, 90
minutes for the ciclosporin A phase.
2.3. Drug Analysis. Lopinavir and ritonavir were measured
simultaneously on a 100μL sample to which an internal
standard (clazepam) was added. The extraction was per-
formed with ethyl acetate in alkaline medium. The range of
concentrations was 0.2 to 20mg/L for lopinavir and 0.05 to
5mg/L for ritonavir. The drugs were separated isocratically
on a nucleoside C8 3μm (F 67722; 125∗4.6mm; Macherey-
Nagel Hoerdt, Hoerdt, France) with buﬀer (tetramethylam-
monium perchlorate 0.01mol/L in a 0.01% triﬂuoroacetic
acid (pH = 3) and acetonitrile [60 : 40]). Ultraviolet
absorbance at 205nm was used for detection. The lower
limitsofquantiﬁcation(LOQ)were0.2and0.05forlopinavir
and ritonavir, respectively. Mean intra-assay precision at
the low-quality control was lower than 12.5% and accuracy
(percent deviation from expected) at the LOQ was less than
10%. The overall recovery was 80%.
2.4. Pharmacokinetic Analysis. The results were reported as a
Fetal Transfer Rate (FTR = Cf/Cm, Cf as fetal concentration
and Cm as maternal concentration) and as a Clearance Index
(ClI = FTRcompound/FTRantipyrin) [12].
2.5. P-glycoprotein Expression on Placentas. This analysis
was previously used to study the quantitative expressionObstetrics and Gynecology International 3
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Figure 1: Variation of clearance index of lopinavir at diﬀerent
albumin perfused concentrations (for 10g/L n = 3, for 30g/L n = 3
and for 40g/L n = 5). Linear regression (r2 = 0.886).
during pregnancy [6]. Trophoblast cells were scrapped,
centrifuged, and incubated in a lysis buﬀer containing
10mM Tris-HCl (pH 7.4), 5mM EDTA (pH 8), 126mM
NaCl,1%triton,0.1%SDS,proteaseinhibitors(1mMPMSF,
5μg·mL
−1 pepstatin, 0.5mg·mL
−1 leupeptin, 31.2mg·mL
−1
benzamidine, 5μg·mL
−1 aprotinin) for 30 minutes at
4◦C. After incubation, the suspension was centrifuged at
12000g for 20 minutes at 4◦C. Protein concentration
was determined using the colorimetric Bicinchoninic Assay
kit (Sigma-Aldrich, Saint-Quentin Fallavier, France), with
bovine serum albumin as standard. Ten micrograms of
proteins were subjected to SDS-polyacrylamide gel elec-
trophoresis with an 8% polyacrylamide gel and transferred
onto a nitrocellulose membrane (Amersham, Orsay, France).
The nitrocellulose membranes were then incubated with
primary antibody (C219, diluted 1 : 100; DAKO, Denmark)
followed by a peroxidase-conjugated antimouse IgG sec-
ondary antibody (diluted 1 : 7500; DAKO, Denmark). The
immunoreactive bands were visualized by the Enhanced
Chemo-Luminescent system (Perkin Elmer Life Science,
Boston, MA, USA). The amount of immunoreactive P-
glycoprotein on placental samples was relatively expressed
to the signal measured in K562R7 extracts. The autora-
diographs of P-glycoprotein protein were scanned and
analyzed by densitometry using the Scion Image program
to obtain a quantitative evaluation of the levels in the
placenta.
2.6. Statistical Analysis. Ap a i r e dS t u d e n t ’ st-test test was
performed to compare datas, expressed as means ± SD,
for the clearance index comparing control and ciclosporin
A phases. An unpaired t-test was performed to compare
as diﬀerent albumin concentrations. The Spearman test to
correlate the clearance index and placental expression of P-
glycoprotein was used. An α risk value of less or equal to
0.05 was considered as signiﬁcant. Statistical analyses were
performed using Graphpad Prism 4 for Windows version
(Graphpad Software, USA).
Table 1: Clearance index of lopinavir (A) and ritonavir (B)
combination at steady state. (mean ± SD). ∗means P ≤ .05
(a)
A Control Ciclosporin A Relative
increase in ClI
Albumin
10g/L
0.401 ±0.058 0.521 ±0.065 ×1.3∗
Albumin 30
and 40g/L
0.007 ±0.027 0.072 ±0.101 ×10.29∗
(b)
B Control Ciclosporin A Relative
increase in ClI
Albumin
10g/L
0.06 ±0.104 0.104 ±0.181 ×1.73
Albumin 30
and 40g/L
00 .071 ±0.103 —
3. Results
The open-open system was used to determine the transfer
rates of lopinavir and ritonavir under steady-state condi-
tions. Eleven placentas were validated for this perfusion.
The maternal concentrations were, respectively, 6.121 ±
1.824mg/Lforlopinavirand3.318±1.134mg/Lforritonavir.
The variation of fetal transfer rate of antipyrin in the control
and ciclosporin A phases (mean of values at 25, 30, 35, and
40 minutes versus 75, 80, 85, and 90 minutes) was collected
atsteadystate.Meanfetaltransferratesofantipyrin(31.7%±
6.31)withciclosporinAandwithout(25.3%±4.51)at10g/L
(95% CI of the diﬀerence [−1.67,14.5], P = .076) and 30
and 40g/L (28% ± 6.91 versus 25.4% ± 8.48, 95% CI of the
diﬀerence [−4.28,9.59], P = .396) were not signiﬁcantly
diﬀerent.
3.1. Albumin Eﬀect. Five placentas were perfused with 40g/L
bovine serum albumin concentration, 3 with 30g/L, and
3w i t h1 0 g / L( Table 1, Figure 1). The clearance index for
lopinavir was signiﬁcantly lower in 30 or 40g/L albumin
concentrations than 10g/L, (10 versus 40g/L, 95% CI
[0.360,0.427], P<. 0001; 10 versus 30g/L, 95% CI
[0.343,0.440], P<. 0001). At higher albumin concentra-
tions there was no diﬀerence (30 versus 40g/L, 95% CI
[−0.022,0.027], P = .822). Clearance index of ritonavir was
low at 10g/L of albumin (0.060 ± 0.089) and was zero at 30
or 40g/L albumin concentrations.
3.2. Placental Transfer of the Lopinavir/Ritonavir Combi-
nation with Ciclosporin A (Figure 2). At 10g/L albumin
concentration, the clearance index of lopinavir increased
signiﬁcantly following the addition of ciclosporin A (95% CI
[−0.197,−0.048], P = .02). At physiological concentrations
of albumin (30 and 40g/L), the diﬀerence was signiﬁcant
(95% CI [−0.156,−0.002], P = .046). The clearance index
of ritonavir increased in the presence of ciclosporin A but it
was not signiﬁcant.4 Obstetrics and Gynecology International
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Figure 2: Variation of clearance index of lopinavir in the control and ciclosporin A phases (mean of values at 25, 30, 35, and 40 minutes
versus 75, 80, 85, and 90 minutes) at low ((a), 10g/L) and physiologic ((b), 30, and 40g/L) albumin concentrations. The lines join the data
f r o mt h es a m ep l a c e n t a( n = 3a t1 0g / L ,n = 3a t3 0g / La n dn = 5 at 40g/L). Mean clearance index of lopinavir (0.401 ± 0.058) with
ciclosporin A (0.521 ± 0.066) at 10g/L (95% CI of the diﬀerence [−0.186,−0.054], P = .016) and 30 and 40g/L (0.007 ± 0.027 versus
0.072 ±0.101, 95% CI of the diﬀerence [−0.156,−0.002], P = .046).
Table 2: Clearance index of lopinavir in the control phase (0–45 minutes) and Pgp placental expression for experiments during the control
phase at physiological albumin concentrations (30–40g/L).
S a m p l e 1 2 345678 9
Relative Pgp expression 1 3.1 3.14 3.59 0.68 2.71 3.38 0.74 0.31
ClI lopinavir — 0 0 0.03 0000 0 . 0 2 5
Pgp: P-glycoprotein, ClI: clearance index. Sample 1: control cell line R7. Samples 2–9: relative expression to sample 1 expression.
12345678 9
Figure 3: Western blot of the P-glycoprotein on placenta perfused
at 30 and 40g/L of albumin (n = 8). Control was on the left.
Sample 1 was control sample; sample 9 was not visible at this time
of exposition.
3.3. Eﬀect of Placental P-Glycoprotein (Table 2, Figure 3).
Expression on placenta of P-glycoprotein was wide (3.06 ±
2.384, covar = 77.91%). There was a low and no signiﬁcant
correlation between expression of the P-glycoprotein and
clearance index of lopinavir without ciclosporin A (r =
0.109).
4. Discussion
In this study, pharmacologic blockade of P-glycoprotein by
ciclosporin A signiﬁcantly increased the placental transfer
of lopinavir. This ﬁnding strongly suggests that under
physiological conditions, P-glycoprotein plays an active role
in decreasing placental transfer of lopinavir from the mother
to the fetus. This is consistent with studies in the rat,
which concluded that P-glycoprotein produced an active
and functional barrier between the maternal and fetal
circulations [13].
Our ﬁndings are also consistent with those of Molsa et al.
on the placental transfer of saquinavir [14]. In this study,
preperfusion with PSC833 or GG918, two inhibitors of the
activity of P-glycoprotein, increased the placental transfer of
saquinavir by 7.9-fold and 6.2-fold, respectively, compared
with control placentas. However, PSC833 had no eﬀect on
the transfer of saquinavir from the fetal to the maternal
direction. In our case, controls were placentas themselves
like recent study realized by Sudhakaran, which eliminates
biases such as diﬀerences between placentas for various
genetic and physiologic reasons [15]. Recently, Agarwal et al.
conﬁrmed on speciﬁc cell cultures that both P-glycoprotein
and MRP2 mediate transport of lopinavir [16]. MRP2 has
low expression on the human placenta and Sudhakaran et al.
suggested for this transporter was unlikely to contribute
signiﬁcantlytolimitingthetransferofthesedrugstothefetus
[15].
Previously, we showed that the mean expression of P-
glycoprotein in human placentas progressively decreases
by twofold decrease between the ﬁrst and third trimesters
[6]. Also, many environmental factors could aﬀect the P-
glycoprotein expression [17]. HIV infection itself may play
ar o l ea ss u g g e s t e di nas t u d yb yo u rg r o u pw h oc o m p a r e d
35 full-term placentas from uninfected women and 24 from
HIV-1 infected women and showed a signiﬁcant 3.3-fold
mean increase in MDR1 placental transcription in HIV-
infected women. In this research, there did not appear to be
intraplacental variations of expression of P-glycoprotein [5].
Our study lacked power to conclude for an high correlationObstetrics and Gynecology International 5
between variation of expression of placental P-glycoprotein
with its activity. Relation to genetic polymorphism of the
MDR-1 gene may play role [18]. The reported eﬀects of
MDR1 SNPs have been inconsistent and, in some cases,
conﬂicting [19]. This may be due to a number of potential
confounding factors of the observed MDR1 polymorphism
eﬀect in vivo issues, as suggested by Marzolini et al. [19],
including MDR1 haplotypes, environmental factors, and
study design.
In our study, the albumin concentration in the perfusate
stands out as an important factor in transplacental transfer
of lopinavir. This conﬁrms previous results from our group
[2]. At low albumin concentrations, the transfer of lopinavir
and ritonavir was compatible with passive diﬀusion, whereas
the clearance decreased signiﬁcantly at physiological albu-
min concentrations (30 and 40g/L). Sudhakaran et al.
determined the protein binding characteristics of two PIs,
indinavir and saquinavir [20, 21]. They were examined
in maternal and umbilical cord plasma. Both PIs were
signiﬁcantly less bound in umbilical cord than maternal
plasma, indicating that the low cord-mother ratios of total
drug were inﬂuenced by diﬀerential protein binding and
the nature of this binding protein (alpha1-acid glycoprotein,
human serum albumin).
Our ﬁndings indicate that P-glycoprotein plays a role in
the human placental barrier, even at physiological albumin
concentration. This may have important clinical implica-
tions. In particular interaction with P-glycoprotein may lead
to diﬀerence in fetal exposure to maternally administrated
drugs. For instance, calcium blockade currently used for
tocolysis or hypertension during pregnancy is P-glycoprotein
inhibitor, which may increase the transfer of P-glycoprotein
substrates by several folds [22–24].
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